Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease

The number of biologics approved for Crohn disease (CD) is increasing. This has spurred interest in how immune-modulating treatments are used during the course of disease. Our results showed use of early immune-modulating treatment increased from 2010 to 2018. Patients with this treatment pattern al...

Full description

Saved in:
Bibliographic Details
Published in:Journal of managed care & specialty pharmacy 2022-08, Vol.28 (8), p.849-861
Main Authors: Shah, Kanya K, Caffrey, Aisling R, Szczotka, Andy, Belazi, Dea, Kogut, Stephen J
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The number of biologics approved for Crohn disease (CD) is increasing. This has spurred interest in how immune-modulating treatments are used during the course of disease. Our results showed use of early immune-modulating treatment increased from 2010 to 2018. Patients with this treatment pattern also had higher nondrug medical costs in the first year compared with people initially prescribed typical agents. Future research should look at long-term costs and outcomes in a real-world setting.
ISSN:2376-0540
2376-1032
DOI:10.18553/jmcp.2022.28.8.849